|
Synonyms: isoproterenol | Isuprel® | Medihaler-Iso®
isoprenaline is an approved drug
Compound class:
Synthetic organic
Comment: Isoprenaline is a β-adrenoceptor agonist drug.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor. Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733] |
|
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385] |
|
3. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. PLoS ONE, 5 (11): e15487. [PMID:21152092] |
|
4. Baker JG. (2010)
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599] |
|
5. Baker JG, Hall IP, Hill SJ. (2002)
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br J Pharmacol, 137 (3): 400-8. [PMID:12237261] |
|
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341] |
|
7. Baker JG, Hall IP, Hill SJ. (2003)
Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses. Mol Pharmacol, 64 (3): 679-88. [PMID:12920204] |
|
8. Baker JG, Hall IP, Hill SJ. (2004)
Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol Pharmacol, 65 (4): 986-98. [PMID:15044629] |
|
9. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. (2008)
Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor. Mol Pharmacol, 74 (5): 1246-60. [PMID:18687809] |
|
10. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PLoS One, 8 (11): e77582. [PMID:24250787] |
|
11. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor. Br J Pharmacol, 112 (3): 911-9. [PMID:7921620] |
|
12. De Pascali F, Ippolito M, Wolfe E, Komolov KE, Hopfinger N, Lemenze D, Kim N, Armen RS, An SS, Scott CP et al.. (2022)
β2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β2 -adrenoceptor with possible implications for the treatment of asthma. Br J Pharmacol, 179 (19): 4692-4708. [PMID:35732075] |
|
13. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors. Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332] |
|
14. Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. (1988)
Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. Proc Natl Acad Sci USA, 85 (24): 9494-8. [PMID:2849109] |
|
15. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004)
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417] |
|
16. Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T, Kurose H. (1999)
Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. Mol Pharmacol, 56 (5): 875-85. [PMID:10531390] |
|
17. Molenaar P, Sarsero D, Arch JR, Kelly J, Henson SM, Kaumann AJ. (1997)
Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol, 120 (2): 165-76. [PMID:9117106] |
|
18. Méjean A, Guillaume JL, Strosberg AD. (1995)
Carazolol: a potent, selective beta 3-adrenoceptor agonist. Eur J Pharmacol, 291 (3): 359-66. [PMID:8719421] |
|
19. Popp BD, Hutchinson DS, Evans BA, Summers RJ. (2004)
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol, 484 (2-3): 323-31. [PMID:14744619] |
|
20. Sato Y, Kurose H, Isogaya M, Nagao T. (1996)
Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol, 315 (3): 363-7. [PMID:8982677] |
|
21. Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. (2013)
In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther, 344 (1): 218-30. [PMID:23131596] |
|
22. Strosberg AD. (1997)
Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260] |
|
23. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. (2013)
The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors. Eur J Pharmacol, 720 (1-3): 124-30. [PMID:24183974] |
|
24. Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. (2023)
Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. PLoS One, 18 (9): e0290685. [PMID:37656760] |